FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2249-2250 November 23, 2006 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Stone, G. W. PubMed Citation

The treatment of patients with acute coronary syndromes is straightforward in principle but complex in practice. With the increase in referrals of moderate- or high-risk patients for invasive cardiac procedures to improve clinical outcomes,¹ there is a need to define the antithrombotic regimen that is optimal for both stabilizing the underlying active atherosclerotic plaque and minimizing the risk of bleeding.

The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, reported in this issue of the Journal,² evaluated the role of a thrombin-specific anticoagulant — bivalirudin — as part of a blended medical and invasive strategy for patients with acute . . . [Full Text of this Article]

Source Information

From the Ocala Heart Institute, Munroe Regional Medical Center, Ocala, FL.

This article has been cited by other articles:

• (2006). Is Bivalirudin a Good Antithrombotic Choice in ACS Patients?. Journal Watch Cardiology 2006: 1-1 [Full Text]